ATE409193T1 - Verfahren zur acylierung von peptiden und proteinen - Google Patents

Verfahren zur acylierung von peptiden und proteinen

Info

Publication number
ATE409193T1
ATE409193T1 AT00910573T AT00910573T ATE409193T1 AT E409193 T1 ATE409193 T1 AT E409193T1 AT 00910573 T AT00910573 T AT 00910573T AT 00910573 T AT00910573 T AT 00910573T AT E409193 T1 ATE409193 T1 AT E409193T1
Authority
AT
Austria
Prior art keywords
acylation
peptides
proteins
relates
compounds useful
Prior art date
Application number
AT00910573T
Other languages
English (en)
Inventor
Louis Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE409193T1 publication Critical patent/ATE409193T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00910573T 1999-03-17 2000-03-16 Verfahren zur acylierung von peptiden und proteinen ATE409193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99610019 1999-03-17
EP00910573A EP1163211B1 (de) 1999-03-17 2000-03-16 Verfahren zur acylierung von peptiden und proteinen

Publications (1)

Publication Number Publication Date
ATE409193T1 true ATE409193T1 (de) 2008-10-15

Family

ID=26074622

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910573T ATE409193T1 (de) 1999-03-17 2000-03-16 Verfahren zur acylierung von peptiden und proteinen

Country Status (16)

Country Link
EP (2) EP1956000B1 (de)
CN (1) CN1344248A (de)
AT (1) ATE409193T1 (de)
AU (1) AU3273500A (de)
BR (1) BR0009040A (de)
CA (1) CA2361830A1 (de)
CZ (1) CZ20013018A3 (de)
DE (1) DE60040333D1 (de)
ES (1) ES2315226T3 (de)
HU (1) HUP0200297A3 (de)
IL (1) IL144989A0 (de)
NO (1) NO20014508L (de)
PL (1) PL351326A1 (de)
RU (1) RU2001128068A (de)
WO (1) WO2000055119A1 (de)
ZA (1) ZA200106884B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
AU2002355161A1 (en) * 2001-07-24 2003-02-17 Novo Nordisk A/S Method for making acylated polypeptides
AU2002355160A1 (en) * 2001-07-24 2003-02-17 Novo Nordisk A/S Method for making acylated polypeptides
JP4227894B2 (ja) * 2001-08-23 2009-02-18 イーライ リリー アンド カンパニー グルカゴン様ペプチド１アナログ
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
PL210455B1 (pl) * 2002-09-25 2012-01-31 Novo Nordisk As Sposób otrzymywania acylowanych peptydów
US7067488B2 (en) 2002-09-25 2006-06-27 Theratechnologies Inc. Modified GLP-1 peptides with increased biological potency
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP4965446B2 (ja) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
ES2458991T3 (es) 2004-11-12 2014-05-07 Novo Nordisk A/S Formulaciones estables de péptidos insulinotrópicos
EP2280993A1 (de) 2008-05-15 2011-02-09 Novo Nordisk A/S Reinigung von durch festphasensynthese hergestellten peptiden
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
CA2747109A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
MX2011006315A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
WO2011161125A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
JP2014504597A (ja) 2011-01-20 2014-02-24 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体とインスリン類似体の組合せ物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (de) 2011-05-10 2014-03-19 Zealand Pharma A/S Signalisierungsauswahlverbindungen mit einem zweifach-glu-glp-1-agonisten
AR088636A1 (es) 2011-11-03 2014-06-25 Zealand Pharma As Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
EP2844670B1 (de) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-artige peptid-2-analoga (glp-2-)analoga
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AR094181A1 (es) 2012-12-21 2015-07-15 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
HUE057168T2 (hu) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc A hepcidin analógjai és ezek alkalmazása
MX2015016564A (es) 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
AR096789A1 (es) 2013-07-04 2016-02-03 Novo Nordisk As Derivados de péptidos similares a glp-1 y usos de los mismos
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN104558097A (zh) * 2014-05-20 2015-04-29 广东东阳光药业有限公司 肽的酰化方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
EP3226906B1 (de) 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1-derivate und verwendungen davon
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3271381B1 (de) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin-analoga
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3196206A1 (de) 2016-01-20 2017-07-26 Lonza Ltd Verfahren zur herstellung von liraglutid
US11236123B2 (en) 2016-01-20 2022-02-01 Polypeptide Laboratories Holding (Ppl) Ab Method for preparation of peptides with psWang linker
EP3205660A1 (de) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Verfahren zur herstellung von peptiden mit pswang-linker
EP3205664A1 (de) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Verfahren zur herstellung von liraglutide mithilfe eines bal-linker
EP3432906A4 (de) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. Verfahren zur synthetisierung von alpha4beta7-peptid-antagonisten
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
KR20190101990A (ko) 2016-12-05 2019-09-02 뉴리타스 리미티드 펩티드 wkdeagkplvk를 포함하는 조성물
EP3329930A1 (de) 2016-12-05 2018-06-06 Nuritas Limited Pharmazeutische zusammensetzungen
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CA3043151A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
SG11202008177WA (en) 2018-02-27 2020-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
EP3897570A1 (de) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmazeutische zusammensetzung mit glp-1-analog
CN111909073A (zh) * 2019-05-10 2020-11-10 江苏万邦医药科技有限公司 一种制备高纯度脂肪酸衍生物的方法
EP3997105A4 (de) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
EP4126003A1 (de) 2020-03-30 2023-02-08 Zealand Pharma A/S Duale glp-1-/glp-2-agonisten
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
AU2022339044A1 (en) 2021-09-03 2024-03-14 Zealand Pharma A/S Dosage regime
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
ATE356830T1 (de) * 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action

Also Published As

Publication number Publication date
CA2361830A1 (en) 2000-09-21
DE60040333D1 (de) 2008-11-06
ES2315226T3 (es) 2009-04-01
EP1163211A1 (de) 2001-12-19
CZ20013018A3 (cs) 2002-02-13
EP1956000B1 (de) 2016-10-05
EP1163211B1 (de) 2008-09-24
HUP0200297A2 (en) 2002-06-29
IL144989A0 (en) 2002-06-30
EP1956000A1 (de) 2008-08-13
BR0009040A (pt) 2001-12-18
PL351326A1 (en) 2003-04-07
ZA200106884B (en) 2002-03-01
WO2000055119A1 (en) 2000-09-21
AU3273500A (en) 2000-10-04
RU2001128068A (ru) 2004-02-20
CN1344248A (zh) 2002-04-10
NO20014508D0 (no) 2001-09-17
HUP0200297A3 (en) 2002-09-30
NO20014508L (no) 2001-09-17

Similar Documents

Publication Publication Date Title
ATE409193T1 (de) Verfahren zur acylierung von peptiden und proteinen
DE69433934D1 (de) Verfahren und Zusammensetzungen zur erhöhten Proteinproduktion von rekombinanter DNA
DE60041119D1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE60031030D1 (de) Verfahren zur Identifizierung von Peptiden und Proteinen mittels Massenspektromterie
DE60026452D1 (de) Verfahren zur Identifizierung von Peptidensequenzen und Proteinensequenzen mittels Massenspektromterie
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
NO972264L (no) Fremgangsmåter for behandling av multippel sklerose ved bruk av peptidanaloger av human myelin basis protein
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
DE69534702D1 (de) Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
HU9200548D0 (en) Improved activity process of recombined proteins
ATE168719T1 (de) Osteogene peptide
ATE102949T1 (de) Verfahren zur herstellung von retro-inversopeptiden und dessen zwischenprodukte.
ATE97421T1 (de) Gentechnologisch hergestellter pankreatischer sekretorischer trypsininhibitor und seine varianten.
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE69432449D1 (de) Verfahren zur Herstellung von hydrophoben Polypeptiden, Proteinen und Peptiden
DE3650676T2 (de) Verfahren und mittel zur sortierung und bestimmung biologischer informationen
DE69838667D1 (de) Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel
DE60138703D1 (de) Transportpeptide abgeleitet von erns protein
DE69816622D1 (de) Verfahren zur Steigerung der Expression von Fremdproteinen
DE69827268D1 (de) Verfahren und zusammensetzungen zur raschen aufreinigung von proteasomen und verfahren zur verwendung entsprechender komponenten
DE69434914D1 (de) Verfahren und zusammensetzungen zur herstellung von rekombinantem osteogenischem protein
DE69806747T2 (de) Verfahren zur veresterung von aminosäuren und proteinen
ATE282088T1 (de) Aminopeptidase, welche von bacillus licheniformis abstammt und verfahren zur herstellung von proteinen des natürlichen typs
DE59802465D1 (de) Verfahren und kit zur identifizierung von wechselwirkungen zwischen proteinen bzw. peptiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties